<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00623441</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol Final version1.1</org_study_id>
    <nct_id>NCT00623441</nct_id>
    <nct_alias>NCT00265668</nct_alias>
  </id_info>
  <brief_title>E-Five Registry: A World-Wide Registry With The Endeavor Zotarolimus Eluting Coronary Stent</brief_title>
  <acronym>eFive</acronym>
  <official_title>E-Five Registry: To Evaluate the 'Real World' Clinical Performance of the Medtronic Endeavor ABT-578 Eluting Coronary Stent System; A Prospective, Multicenter Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The safety and efficacy of the Endeavor(TM) ABT-578 Eluting Coronary Stent System has been
      assessed in a series of studies. The stent is coated with a proprietary drug compound that is
      designed to reduce restenosis.

      This prospective multi-center study has been initiated:

        -  To document the acute and mid-term safety and overall clinical performance of the stent
           system in a &quot;real world&quot; patient population requiring stent implantation.

        -  To assess the event rate in patient subgroups with specific clinical indications and/or
           vessel or lesion characteristics.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MACE (Major Adverse Cardiac Events)</measure>
    <time_frame>12 Months</time_frame>
    <description>MACE is defined as death, myocardial infarction (Q-wave and non-Q wave), emergent cardiac bypass surgery, or target lesion revascularization (repeat PTCA (Percutaneous Transluminal Coronary Angioplasty) or CABG (Coronary Artery Bypass Graft surgery))</description>
  </primary_outcome>
  <enrollment type="Actual">8314</enrollment>
  <condition>Coronary Artery Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endeavor Zotarolimus Eluting Coronary Stent</intervention_name>
    <description>Drug eluting stent</description>
    <other_name>Endeavor Stent</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Real-world patients requiring drug eluting stent implantation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is &gt;18 years of age (or minimum age as required by local regulation)

          -  The patient has consented to participate by signing the &quot;Patient Informed Consent
             Form&quot; and/or has authorized the collection and release of his medical information by
             signing the &quot;Patient Data Release Consent Form&quot;.

          -  The patient is suitable for implantation of one or more Endeavor(TM) ABT-578 Eluting
             Coronary Stent System in one or more native artery target lesions.

          -  Lesion length and vessel diameter of the target lesion(s) are according to the
             &quot;Indications for Use&quot; as mentioned in the &quot;Instructions for Use&quot; that comes with every
             Endeavor(TM) ABT-578 Eluting Coronary Stent System.

          -  The patient is willing and able to cooperate with registry procedures and required
             follow up visits.

        Exclusion Criteria:

          -  Women with known pregnancy or who are lactating.

          -  Patients with hypersensitivity or allergies to aspirin, heparin, clopidogrel,
             ticlopidine, drugs such as ABT-578, rapamycin, tacrolimus, sirolimus or similar drugs,
             or any other analogue or derivative, cobalt, chromium, nickel, molybdenum or contrast
             media.

          -  Patients in whom anti-platelet and/pr anticoagulation therapy is contraindicated.

          -  Patients who are judged to have a lesion that prevents complete inflation of an
             angioplasty balloon.

          -  Current medical condition with a life expectancy of less than 12 months.

          -  The subject is participating in another device or drug study. Subject must have
             completed the follow-up phase of any previous study at least 30 days prior to
             enrollment in this trial. The subject may only be enrolled in this E-five registry
             once.

          -  Patients with medical conditions that preclude the follow-up as defined in the
             protocol or that otherwise limits participation in this registry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian T Meredith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Monash Medical Centre, Melbourne, Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chaim Lotan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah University Hospital, Jerusalem, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin T Rothman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>London Chest Hospital, London, United Kingdom</affiliation>
  </overall_official>
  <link>
    <url>http://www.medtronic.com/</url>
  </link>
  <link>
    <url>http://www.endeavorstent.com/</url>
  </link>
  <reference>
    <citation>Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, MÃ¼nzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE; ENDEAVOR II Investigators. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006 Aug 22;114(8):798-806. Epub 2006 Aug 14.</citation>
    <PMID>16908773</PMID>
  </reference>
  <results_reference>
    <citation>Jain AK, Meredith IT, Lotan C, Rothman MT, Pateraki S; E-Five Investigators. Real-world safety and efficacy of the endeavor zotarolimus-eluting stent: early data from the E-Five Registry. Am J Cardiol. 2007 Oct 22;100(8B):77M-83M.</citation>
    <PMID>17950836</PMID>
  </results_reference>
  <results_reference>
    <citation>Lotan C, Meredith IT, Mauri L, Liu M, Rothman MT; E-Five Investigators. Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the E-Five registry. JACC Cardiovasc Interv. 2009 Dec;2(12):1227-35. doi: 10.1016/j.jcin.2009.10.001. Erratum in: JACC Cardiovasc Interv. 2010 Feb;3(2):264.</citation>
    <PMID>20129549</PMID>
  </results_reference>
  <results_reference>
    <citation>Jain AK, Lotan C, Meredith IT, Feres F, Zambahari R, Sinha N, Rothman MT; E-Five Registry Investigators. Twelve-month outcomes in patients with diabetes implanted with a zotarolimus-eluting stent: results from the E-Five Registry. Heart. 2010 Jun;96(11):848-53. doi: 10.1136/hrt.2009.184150.</citation>
    <PMID>20478863</PMID>
  </results_reference>
  <results_reference>
    <citation>Meredith I, Rothman M, Erglis A, Parikh K, Lotan C; E-Five Investigators. Extended follow-up safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: two-year follow-up from the E-Five Registry. Catheter Cardiovasc Interv. 2011 Jun 1;77(7):993-1000. doi: 10.1002/ccd.22803. Epub 2010 Dec 3.</citation>
    <PMID>20853351</PMID>
  </results_reference>
  <results_reference>
    <citation>Lotan C, Meredith IT, Jain A, Feres F, Firszt A, Garcia AF, Rothman MT. Clinical outcomes by geographic region for patients implanted with the zotarolimus-eluting stent. Arq Bras Cardiol. 2011 May;96(5):353-62. Epub 2011 Apr 1. English, Portuguese, Spanish.</citation>
    <PMID>21468534</PMID>
  </results_reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2008</study_first_submitted>
  <study_first_submitted_qc>February 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2008</study_first_posted>
  <results_first_submitted>September 1, 2009</results_first_submitted>
  <results_first_submitted_qc>November 14, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 16, 2011</results_first_posted>
  <last_update_submitted>October 26, 2015</last_update_submitted>
  <last_update_submitted_qc>October 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Drug-eluting stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Consecutive patients with an indication for coronary stent implantation according to the Instructions For Use of the Endeavor Coronary Stent, in whom it is an intent to implant one or more Endeavor Coronary Stents should be included (provided patient consent).</recruitment_details>
      <pre_assignment_details>All enrolled subjects were followed for 12 months. An extended 2-year follow-up was performed in 2116 subjects from 26 centers.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Endeavor Coronary Stent</title>
          <description>Patients with an indication for a percutaneous coronary intervention with implantation with a drug eluting stent</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8314"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8314">12 months follow-up compliance was 94.2%</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Endeavor Coronary Stent</title>
          <description>Patients with an indication for a percutaneous coronary intervention with implantation with a drug eluting stent</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8314"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.29" spread="11.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1940"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Southeast Asia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="879"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pacifica</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes Mellitus</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>IDDM (Insulin Dependent Diabetes Mellitus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-IDDM (Non-Insulin Dependent Diabetes Mellitus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Diabetes Mellitus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>MACE (Major Adverse Cardiac Events)</title>
        <description>MACE is defined as death, myocardial infarction (Q-wave and non-Q wave), emergent cardiac bypass surgery, or target lesion revascularization (repeat PTCA (Percutaneous Transluminal Coronary Angioplasty) or CABG (Coronary Artery Bypass Graft surgery))</description>
        <time_frame>12 Months</time_frame>
        <population>Intention to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Endeavor Coronary Stent</title>
            <description>Patients with an indication for a percutaneous coronary intervention with implantation with a drug eluting stent</description>
          </group>
        </group_list>
        <measure>
          <title>MACE (Major Adverse Cardiac Events)</title>
          <description>MACE is defined as death, myocardial infarction (Q-wave and non-Q wave), emergent cardiac bypass surgery, or target lesion revascularization (repeat PTCA (Percutaneous Transluminal Coronary Angioplasty) or CABG (Coronary Artery Bypass Graft surgery))</description>
          <population>Intention to Treat (ITT)</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Endeavor Coronary Stent</title>
          <description>Patients with an indication for a percutaneous coronary intervention with implantation with a drug eluting stent</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="7832"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Death</sub_title>
                <counts group_id="E1" events="135" subjects_affected="135" subjects_at_risk="7832"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7832"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that results communications are provided to the sponsor at least 90 days prior to submittal for publication or presentation. The sponsor shall not require changes beyond the extent necessary to allow the sponsor to protect its rights in copyrightable material, and to check for technical correctness.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Data collection in this large global registry was limited to MACE (major adverse cardiac events) defined as the composite endpoint of death, myocardial infarction (Q- and non-Q-wave), emergent cardiac bypass surgery and TLR.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sofia Pateraki, MSc - Sr. Clinical Research Specialist</name_or_title>
      <organization>Medtronic Bakken Research Center</organization>
      <phone>+31 43 3566785</phone>
      <email>sofia.pateraki@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

